Transthyretin-mediated Amyloidosis With Cardiomyopathy
1 clinical trials · Condition
◉ Watch Transthyretin-mediated Amyloidosis With Cardiomyopathy
| Record | Firm | Date |
|---|---|---|
| Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy (NCT05505838) | Alnylam Pharmaceuticals |
Track Transthyretin-mediated Amyloidosis With Cardiomyopathy automatically
Every clearance here is in the API, with alerts when new ones post.